Skip to content

Risk Factors Contributing to the Development of Microalbuminuria

Risk Factors Contributing to the Development of Microalbuminuria Over a 5 Year Period

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00572403
Enrollment
10
Registered
2007-12-13
Start date
2007-12-31
Completion date
2008-04-30
Last updated
2011-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microalbuminuria

Keywords

microalbuminuria, risk factors

Brief summary

This research project will look at the relationship between baseline variables, and the new onset of microalbuminuria and the response to treatment with an angiotensin receptor blocker, losartan, in a cohort of 246 early hypertensives and normotensives who are being brought back for a 4-5 year follow up visit as part of a continuing project. We hypothesize that the new onset of microalbuminuria is associated with higher blood pressure levels at baseline and 1 year as well as being associated with elevated left ventricular mass index. The rate of new onset microalbuminuria in non-diabetics is not established and this prospective study will provide data.

Detailed description

The primary objective of this research project is to determine risk factors related to the development of microalbuminuria. The secondary objective is to determine whether uric acid levels at the final visit are correlated with the onset of microalbuminuria. Of participants returning for a 4-5 year follow up visit as part of a continuing project, we will examine the proportion that have developed microalbuminuria. Subjects found to have microalbuminuria will be offered therapy with the ARB losartan and will be followed at three months to determine if there has been a reduction in levels.

Interventions

None listed

Sponsors

Merck Frosst Canada Ltd.
CollaboratorINDUSTRY
Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* participation in the Double Exposure study * elevated microalbuminuria

Design outcomes

Primary

MeasureTime frame
To determine risk factors related to the development of microalbuminuria.3 months

Secondary

MeasureTime frame
To determine whether uric acid levels at the final visit are correlated with the onset of microalbuminuria.3 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026